Fractyl Health (GUTS) Gross Margin (2023 - 2024)
Fractyl Health's (GUTS) quarterly Gross Margin came in at 100.0% in Q4 2024, up 2857.0% YoY from 3.38% in Q1 2024, and up 100.0% on a QoQ basis from 50.0% in Q3 2024.
Fractyl Health (GUTS) Gross Margin (2023 - 2024) Analysis & Trends
Fractyl Health (GUTS) has 2 years of Gross Margin data on file, last reported at 100.0% in Q4 2024.
- Quarterly Gross Margin rose 2857.0% year-over-year to 100.0% in Q4 2024, while the trailing twelve-month figure through Dec 2024 was 46.24% (up 1040.0% YoY) and the FY2024 annual result came in at 46.24%, up 1040.0% from the prior year.
- Gross Margin improved to 100.0% in Q4 2024, from 50.0% in the prior quarter.
- In the past five years, Gross Margin ranged from a high of 100.0% in Q4 2024 to a low of 30.56% in Q3 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.66 Bn | 131.81 Bn | 2.84 Bn | 85.33% |
| 2 | Regeneron Pharmaceuticals | 86.52 Bn | 78.52 Bn | 3.93 Bn | 91.59% |
| 3 | Argenx Se | 65.30 Bn | 60.11 Bn | 1.37 Bn | 90.43% |
| 4 | Moderna | 59.18 Bn | 54.04 Bn | 52.00 Mn | 35.86% |
| 5 | BeOne Medicines | 42.08 Bn | 36.98 Bn | 1.53 Bn | 89.76% |
| 6 | Alnylam Pharmaceuticals | 31.77 Bn | 28.46 Bn | 992.69 Mn | 76.90% |
| 7 | BioNTech SE | 28.13 Bn | 9.74 Bn | 668.28 Mn | 63.27% |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 84.20% |
| 9 | Royalty Pharma | 27.16 Bn | 26.32 Bn | - | - |
| 10 | Fractyl Health | 124.13 Mn | 124.13 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 100.00% |
| Sep 30, 2024 | 50.00% |
| Jun 30, 2024 | 44.19% |
| Mar 31, 2024 | 42.42% |
| Dec 31, 2023 | 71.43% |
| Sep 30, 2023 | 30.56% |
| Jun 30, 2023 | 34.72% |
| Mar 31, 2023 | 40.00% |